Joseph F. Goldberg

Featured in: Favicon

jamanetwork.com Favicon

tandfonline.com Favicon

medscape.com Favicon

medicinenet.com Favicon

jta.org

dovepress.com Favicon

jdsupra.com Favicon

healio.com Favicon

psychiatryonline.org Favicon

pressofatlanticcity.com + 6 more

Articles

Re-Affirming Evidence-Based Psychiatric Care: A Joint Statement on Psychotropic Medication Safety

1 month ago | psychiatrictimes.com | Joseph F. Goldberg |Heidi Anne Duerr

On March 21, 2025, 6 psychiatric organizations published a joint statement to reaffirm the safety and efficacy of psychotropic medications when used appropriately. The statement was aimed to bring clarity following an executive order questioning the safety of various psychotropic medications.
Drug-Drug Interactions with VMAT-2 Inhibitors Used for Tardive Dyskinesia

Oct 22, 2024 | medcentral.com | Joseph F. Goldberg

Drug-drug interactions derive from pharmacokinetic factors and/or pharmacodynamic effects. The following article summarizes key points for physicians about drug-drug interactions (DDIs) to consider when prescribing VMAT-2 inhibitors to treat tardive dyskinesia, namely, valbenazine and deutetrabenazine. Pharmacodynamic ConsiderationsIn FDA registration trials of valbenazine for tardive dyskinesia, somnolence was the most commonly observed adverse event (AE).
Pseudospecific and Transdiagnostic Symptom Targeting in Clinical Trials

May 30, 2024 | psychiatrictimes.com | Joseph F. Goldberg

CONFERENCE REPORTERIn this Mental Health Minute, Joseph F. Goldberg, MD, joins Psychiatric Times® live from the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting and gives us a preview of his upcoming panel presentation, “Pseudospecific Versus Transdiagnostic Symptom Targeting in Pharmacotherapy Trials: Agitation, Attention, Anhedonia, and Mood Instability.” The full transcript is below. Hi, I am Dr Joseph Goldberg.
An Artisanal Approach to Care: A Conversation with Joseph F. Goldberg, MD

May 5, 2024 | psychiatrictimes.com | Joseph F. Goldberg |John J. Miller

CONFERENCE REPORTERJoseph F. Goldberg, MD, and Psychiatric Times Editor-in-Chief, John J. Miller, MD, sat down at the 2024 American Psychiatric (APA) Annual Meeting to discuss Goldberg's new book with Stephen Stahl, MD, PhD, as well as Goldberg's APA session, "Iterative Psychopharmacology: How to Apply Principles of Clinical Reasoning and Decision Analytics to Everyday Practice."Dr Goldberg is a clinical professor of Psychiatry, The Mount Sinai School of Medicine.
Valproate and Weight Gain: A New Look at an Old Problem

Mar 27, 2024 | psychiatrist.com | Joseph F. Goldberg

See article by Grosu et al The once-central role for antimanic mood stabilizers such as lithium and valproate to treat bipolar disorder has steadily declined amid the increasing use of second generation antipsychotics (SGAs), both short- and long-term, regardless of psychosis.1 Use of valproate, in particular, may have declined in bipolar disorder not just as an artifact of promotional nonsupport since losing its patent exclusivity, or growing awareness about its teratogenicity,2 but also in...
Where Does Lamotrigine Fit in the Pharmacotherapy of Mood Disorders?

Jan 31, 2024 | psychiatrist.com | Joseph F. Goldberg

The clinical trials evidence base with lamotrigine places it in an often poorly understood niche within psychopharmacology. Its demonstrated efficacy, based on FDA registration trials, is to prevent impending occurrences of new mood episodes—predominantly depressions, rather than manias—in people with bipolar I disorder.
Tardive Dyskinesia and Psychosocial Impact on Caregivers

Jan 12, 2024 | medcentral.com | Joseph F. Goldberg

Individuals with tardive dyskinesia are often less aware of the presence of involuntary movements than are those around them. Yet, prominent involuntary movements can be disfiguring, elicit unwanted attention, and may reinforce biases and prejudices about psychiatric medicines and mental health stigma.
GLP-1 Agonists for Weight Loss: What You Need to Know

Jul 12, 2023 | medscape.com | Joseph F. Goldberg

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel Evidence suggests substantial beneficial effects on weight and glycemic dysregulation Abstract and Introduction Introduction Obesity and overweight, with or without metabolic dysregulation, pose vexing problems for many patients with mood, anxiety, or psychotic disorders.
Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder

Jun 26, 2023 | tandfonline.com | Justin Faden |Joseph F. Goldberg |Leslie Citrome

Bipolar mania is associated with elevated mood and increased activity and/or energy which can precipitate agitation and result in patient and staff injury. Episodic agitation associated with bipolar disorder necessitates prompt intervention and is needed to prevent symptom escalation. Traditional oral treatment options are non-traumatizing and easy to administer, but have a slow onset-of-action with erratic absorption through the gastrointestinal system.
In Memoriam: Robert M. A. Hirschfeld, MD, 1943-2023

Mar 20, 2023 | psychiatrist.com | Joseph F. Goldberg

menu This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions. In Memoriam Joseph F. Goldberg, MD Published: March 20, 2023 J Clin Psychiatry 2023;84(3):23f14847 To share: https://doi.org/10.4088/JCP.23f14847 © 2023 Physicians Postgraduate Press, Inc. The last several years have sadly witnessed the passing of a...